Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma
| Autor: | Sharlene Litchy, F. Anthony Greco, Daniel C. Scullin, Paul Richards, John D. Hainsworth, Lisa H. Morrissey, Howard A. Burris, James D. Bearden |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
CD20
medicine.medical_specialty biology business.industry Immunology Cancer Cell Biology Hematology medicine.disease Biochemistry Gastroenterology Lymphoma Surgery Refractory immune system diseases hemic and lymphatic diseases Internal medicine Toxicity Monoclonal medicine biology.protein Rituximab Antibody business medicine.drug |
| Zdroj: | Blood. 95:3052-3056 |
| ISSN: | 1528-0020 0006-4971 |
| Popis: | Rituximab, a chimeric antibody that targets CD20+ B cells, produces a 48% response rate in patients with refractory low-grade non-Hodgkin lymphoma. In this phase II trial, patients with low-grade non-Hodgkin lymphoma who had previously received no systemic therapy were treated with rituximab, 375 mg/m2, administered by IV infusion for 4 consecutive weeks. Patients with objective response or stable disease received repeat 4-week courses of rituximab at 6-month intervals. At the time of initial reevaluation at 6 weeks, 21 of 39 patients (54%) had objective response to treatment, and an additional 14 patients (36%) had stable disease or minor response. Response rates were similar in patients with follicular and small lymphocytic (CLL-type) lymphoma (52% versus 57%, respectively). At present, follow-up is short and only 13 patients have undergone a second course of rituximab treatment. However, 4 additional responses were documented either prior to the second course of rituximab (2 patients) or following the second course (2 patients) and 4 patients improved from partial to complete response. The current response rate is 64%, with 6 complete responses (15%). Treatment with rituximab was well tolerated, with only 1 patient experiencing grade 3/4 infusion-related toxicity. Rituximab is well tolerated and highly active in patients with low-grade non-Hodgkin lymphoma previously untreated with systemic therapy. Although further follow-up is required, the demonstration of minimal toxicity and considerable activity of this new biologic agent represents an important beginning of more specific, less toxic treatment for this important group of cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|